Characteristics of Lung Cancers Harboring NRAS Mutations
- 30 April 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (9), 2584-2591
- https://doi.org/10.1158/1078-0432.ccr-12-3173
Abstract
Purpose: We sought to determine the frequency and clinical characteristics of patients with lung cancer harboring NRAS mutations. We used preclinical models to identify targeted therapies likely to be of benefit against NRAS-mutant lung cancer cells. Experimental Design: We reviewed clinical data from patients whose lung cancers were identified at six institutions or reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) to harbor NRAS mutations. Six NRAS-mutant cell lines were screened for sensitivity against inhibitors of multiple kinases (i.e., EGFR, ALK, MET, IGF-1R, BRAF, PI3K, and MEK). Results: Among 4,562 patients with lung cancers tested, NRAS mutations were present in 30 (0.7%; 95% confidence interval, 0.45%–0.94%); 28 of these had no other driver mutations. 83% had adenocarcinoma histology with no significant differences in gender. While 95% of patients were former or current smokers, smoking-related G:C>T:A transversions were significantly less frequent in NRAS-mutated lung tumors than KRAS-mutant non–small cell lung cancer [NSCLC; NRAS: 13% (4/30), KRAS: 66% (1772/2733), P < 0.00000001]. Five of 6 NRAS-mutant cell lines were sensitive to the MEK inhibitors, selumetinib and trametinib, but not to other inhibitors tested. Conclusion: NRAS mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking. Clin Cancer Res; 19(9); 2584–91. ©2013 AACR.Keywords
Other Versions
This publication has 47 references indexed in Scilit:
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation ProfilingMolecular Cancer Therapeutics, 2012
- Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never SmokersPLOS ONE, 2011
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnnals Of Oncology, 2011
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- New driver mutations in non-small-cell lung cancerThe Lancet Oncology, 2011